Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
- PMID: 36202061
- DOI: 10.2337/dci22-0018
Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
Abstract
A technological solution for the management of diabetes in people who require intensive insulin therapy has been sought for decades. The last 10 years have seen substantial growth in devices that can be integrated into clinical care. Driven by the availability of reliable systems for continuous glucose monitoring, we have entered an era in which insulin delivery through insulin pumps can be modulated based on sensor glucose data. Over the past few years, regulatory approval of the first automated insulin delivery (AID) systems has been granted, and these systems have been adopted into clinical care. Additionally, a community of people living with type 1 diabetes has created its own systems using a do-it-yourself approach by using products commercialized for independent use. With several AID systems in development, some of which are anticipated to be granted regulatory approval in the near future, the joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association has created this consensus report. We provide a review of the current landscape of AID systems, with a particular focus on their safety. We conclude with a series of recommended targeted actions. This is the fourth in a series of reports issued by this working group. The working group was jointly commissioned by the executives of both organizations to write the first statement on insulin pumps, which was published in 2015. The original authoring group was comprised by three nominated members of the American Diabetes Association and three nominated members of the European Association for the Study of Diabetes. Additional authors have been added to the group to increase diversity and range of expertise. Each organization has provided a similar internal review process for each manuscript prior to submission for editorial review by the two journals. Harmonization of editorial and substantial modifications has occurred at both levels. The members of the group have selected the subject of each statement and submitted the selection to both organizations for confirmation.
© 2022 by the American Diabetes Association and the European Association for the Study of Diabetes.
Similar articles
-
Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association.Diabetologia. 2023 Jan;66(1):3-22. doi: 10.1007/s00125-022-05744-z. Epub 2022 Oct 6. Diabetologia. 2023. PMID: 36198829 Free PMC article. Review.
-
Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group.Diabetes Care. 2020 Jan;43(1):250-260. doi: 10.2337/dci19-0062. Epub 2019 Dec 5. Diabetes Care. 2020. PMID: 31806649 Review.
-
Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group.Diabetologia. 2020 Feb;63(2):229-241. doi: 10.1007/s00125-019-05034-1. Diabetologia. 2020. PMID: 31802144
-
Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.Diabetologia. 2015 May;58(5):862-70. doi: 10.1007/s00125-015-3513-z. Epub 2015 Mar 18. Diabetologia. 2015. PMID: 25784563
-
Do-It-Yourself and Commercial Automated Insulin Delivery Systems in Type 1 Diabetes: An Uncertain Area for Canadian Health-care Providers.Can J Diabetes. 2022 Dec;46(8):863-870. doi: 10.1016/j.jcjd.2022.06.003. Epub 2022 Jun 22. Can J Diabetes. 2022. PMID: 35945126 Review.
Cited by
-
Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review.Commun Med (Lond). 2023 Oct 5;3(1):132. doi: 10.1038/s43856-023-00358-x. Commun Med (Lond). 2023. PMID: 37794113 Free PMC article.
-
Use of Open-Source Automated Insulin Delivery Systems in Pregnancies With Type 1 Diabetes.J Diabetes Sci Technol. 2023 Jul;17(4):1126-1128. doi: 10.1177/19322968231169777. Epub 2023 Apr 16. J Diabetes Sci Technol. 2023. PMID: 37062960 Free PMC article. No abstract available.
-
Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey.Diabetes Care. 2024 Jun 1;47(6):941-947. doi: 10.2337/dc23-1765. Diabetes Care. 2024. PMID: 38295397 Free PMC article.
-
Trends and Disparities in Technology Use and Glycemic Control in Type 1 Diabetes.JAMA Netw Open. 2025 Aug 1;8(8):e2526353. doi: 10.1001/jamanetworkopen.2025.26353. JAMA Netw Open. 2025. PMID: 40788645 Free PMC article.
-
A Longitudinal Multimodal Dataset of Type 1 Diabetes.Sci Data. 2025 Aug 7;12(1):1379. doi: 10.1038/s41597-025-05695-1. Sci Data. 2025. PMID: 40775218 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous